Survival function analysis of treatment Interruption for Viral load status and BMI status. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Survival function analysis of viral suppression for BMI status and Treatment Interruption status. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Schematic presentation of sampling of population for analysis. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Survival curve of ART Treatment outcomes. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Incidence of mortality and viral load suppression by demographic characteristics among participants in HIV care facilities in Bauchi State, 2020-2022. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Incidence of ART treatment interruption and LTFU by clinical characteristics <i>among participants in HIV care Facilities in</i> Bauchi State, 2020-2022. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Incidence of ART treatment interruption and LTFU by demographic characteristics among participants in HIV care facilities in Bauchi State, 2020-2022. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Incidence of mortality and viral load suppression by clinical characteristics among participants in HIV care facilities in Bauchi State, 2020-2022. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Cumulative treatment outcomes prevalence rates for patients in ART treatment from year 2020 to 2022 for study participant in Bauchi State. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Survival function analysis for LTFU according to Viral Load status and BMI status. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Demographic characteristics of study participants from two ART facilities in Bauchi state, based on data retrieved covering a three-year period from 2020 to 2022. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Annual incidence rate per 100 person-years trend for ART treatment outcomes. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Comparison of study groups based on patients’ variables before and after administration of study drugs. by Nadia Gul (249538)

Subjects:

Flow chart of patient’s recruitment and participation. by Nadia Gul (249538)

Subjects:

Comparative analyses of group 1 vs group 2 based on various patient characteristics. by Nadia Gul (249538)

Subjects:

Frequency of hypoglycemic episodes in group 1 vs group 2. by Nadia Gul (249538)

Subjects:

Demographics and baseline characteristics of patients. by Nadia Gul (249538)

Subjects:

Impact of group 1 and group 2 drugs on hyperglycemia based on HbA1c levels before and after 3 months of administration. by Nadia Gul (249538)

Subjects:

Serum metabolomic response to aging. by Gwangho Yoon (5771678)

“…<b>(B)</b> Metabolites that decreased with aging. Statistical significance is indicated in the heatmap with asterisks. …”

PBM significantly reduces hyperphosphorylation of tau with no effect on total tau expression. by Kevin J. Johnson (2647639)